Clinical trials for Ovarian / Fallopian tubes / Peritoneum cancer
155 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Ovarian / Fallopian tubes / Peritoneum cancer
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required folate alpha receptor score
Greater than or equal to 75%
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Abbvie
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06824467
#2023-508015-23-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06476184
#2023-508260-30-01
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Other epithelial ovarian cancer
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
36 recruiting sites
ARCAGY/ GINECO GROUP
Phase 3
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
Brain tumors / Central nervous system tumors
Skin cancer
#NCT06471465
#2024-510893-25-00
Required previous treatments
Radiotherapy
9 recruiting sites
Institut de Cancérologie de l'Ouest
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07218809
#2025-520466-22-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07318558
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Required FIGO stages
Stage III
Stage IV
Required disease stage
Localized
Required HRD statuses
HRD Negative
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Surgery
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie B (Sensible au platine avec traitement antérieur par Parpi)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at localized stage
Chemotherapy
Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie A (Résistant au platine)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie C (Sensible au platine naive de traitement par Parpi
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
10 recruiting sites
Eli Lilly et compagnie
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06819007
#2024-516982-35-00
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Mucinous carcinoma
Other epithelial ovarian cancer
Required FIGO stages
Stage III
Stage IV
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded genetic anomalies
BRCA 1/2
10 recruiting sites
Daiichi Sankyo